Growth Metrics

Lucid Diagnostics (LUCD) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to 971.02%.

  • Lucid Diagnostics' EBIT Margin rose 267700.0% to 971.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 1082.17%, marking a year-over-year decrease of 48000.0%. This contributed to the annual value of 1059.64% for FY2024, which is 9371500.0% up from last year.
  • Per Lucid Diagnostics' latest filing, its EBIT Margin stood at 971.02% for Q3 2025, which was up 267700.0% from 948.67% recorded in Q2 2025.
  • Over the past 5 years, Lucid Diagnostics' EBIT Margin peaked at 948.67% during Q2 2025, and registered a low of 18917.11% during Q3 2022.
  • For the 4-year period, Lucid Diagnostics' EBIT Margin averaged around 4248.75%, with its median value being 1283.96% (2023).
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 174959000bps in 2023, then plummeted by -4299700bps in 2025.
  • Over the past 4 years, Lucid Diagnostics' EBIT Margin (Quarter) stood at 13370.54% in 2022, then soared by 92bps to 1101.25% in 2023, then rose by 6bps to 1033.83% in 2024, then increased by 6bps to 971.02% in 2025.
  • Its EBIT Margin was 971.02% in Q3 2025, compared to 948.67% in Q2 2025 and 1508.09% in Q1 2025.